New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 21, 2014
09:02 EDTQCORQuestcor's Acthar shows positive results in clinical study
Questcor announced published results from an investigator-initiated clinical study involving two major academic research centers examining the dosing and effectiveness of H.P. Acthar Gel in 20 patients with nephrotic syndrome due to idiopathic membranous nephropathy. The results demonstrate that Acthar can be a potentially useful therapy for inducing remission of proteinuria in patients suffering from nephrotic syndrome secondary to iMN. Acthar was generally well tolerated by patients, with the most common side effects being mood changes, weight gain and transient insomnia.
News For QCOR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for QCOR

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use